Clinical features of interleukin 10 receptor gene mutations in children with very early-onset inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 60, Issue 3, 2015, Pages 332-338

  Beser, Omer F ^a   Conde, Cecilia Dominguez ^b   Serwas, Nina K ^b   Cokugras, Fugen Cullu ^a   Kutlu, Tufan ^a   Boztug, Kaan ^b,c   Erkan, Tulay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

Author keywords

IL 10; IL 10RA; IL 10RB; pediatric IBD; very early onset inflammatory bowel disease

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; GENOMIC DNA; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 10 RECEPTOR BETA; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; IL10 PROTEIN, HUMAN; IL10RB PROTEIN, HUMAN; INTERLEUKIN 10;

ANUS FISTULA; ARTICLE; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DEMOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; EXON; FOLLOW UP; GENE MUTATION; HUMAN; INFANT; INFLAMMATORY BOWEL DISEASE; INTENSIVE CARE; LEUKOCYTE; LEUKOCYTE COUNT; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; AMINO ACID SUBSTITUTION; COHORT ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; INFLAMMATORY BOWEL DISEASES; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROGNOSIS; RECTAL FISTULA; SEVERITY OF ILLNESS INDEX; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; CHILD, PRESCHOOL; COHORT STUDIES; COMBINED MODALITY THERAPY; CROHN DISEASE; EXONS; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTERLEUKIN-10 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-10 RECEPTOR BETA SUBUNIT; MALE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECTAL FISTULA; SEVERITY OF ILLNESS INDEX;

EID: 84926333929     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000621     Document Type: Article

References (30)

1. Oliva-Hemker M, Escher JC, Moore D, et al. Refractory inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 2008; 47: 266-72
2. Bamias G, Nyce MR, De La Rue SA, et al. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005; 143: 895-904
3. Potzi R, Walgrm M, Lochs H, et al. Diagnostic significance of endoscopic biopsy in Crohn's disease. Endoscopy 1989; 21: 60-2
4. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-94
5. Worthey EA, Mayer AN, Syverson GD, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med 2011; 13: 255-62
6. Speckmann C, Lehmberg K, Albert MH, et al. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol 2013; 149: 133-41
7. Imielinski M, Baldassano RN, Griffiths A, et al. Commonvariants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009; 41: 1335-40
8. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol 2008; 43: 1-17
9. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361: 2033-45
10. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765
11. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135: 1106-13
12. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081-95
13. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigenpresenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444-51
14. Pestka S, Krause CD, Sarkar D, et al. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004; 22: 929-79
15. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008; 121: 1108-11
16. Finbloom DS, Winestock KD. IL-10 induces tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 and STAT3 complexes in human T cells and monocytes. J Immunol 1995; 155: 1079-90
17. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74
18. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (suppl A): 5A-36A.
19. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17: 1314-21
20. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014; 58: 795-806
21. Moyer MS. A collaborative effort to define the epidemiology of pediatric inflammatory bowel disease: what can we learn from children with early-onset disease?. J Pediatr 2005; 146: 7-8
22. Halme L, Paavola-Sakki P, Turunen U, et al. Family and twin studies in inflammatory bowel disease. World J Gastroenterol 2006; 12: 3668-72
23. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012; 143: 347-55
24. Engelhardt KR, Shah N, Faizura-Yeop I, et al. Clinical outcome in IL-10- And IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol 2013; 131: 825-30
25. Glocker EO, Kotlarz D, Klein C, et al. IL-10 and IL-10 receptor defects in humans. Ann N Y Acad Sci 2011; 1246: 102-7
26. Griffiths AM. Growth retardation in early-onset inflammatory bowel disease: should we monitor and treat these patients differently?. Dig Dis 2009; 27: 404-11
27. Ruemmele FM, El Khoury MG, Talbotec C, et al. Characteristics of inflammatory bowel disease with onset during the first year of life. J Pediatr Gastroenterol Nutr 2006; 43: 603-9
28. Cabrera-Abreu JC, Davies P, Matek Z, et al. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004; 89: 69-71
29. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-Analysis. Am J Gastroenterol 2011; 106: 590-9
30. Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 9: CD000478